Last reviewed · How we verify
SYN117 80 mg
At a glance
| Generic name | SYN117 80 mg |
|---|---|
| Sponsor | Biotie Therapies Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pharmacogenetic Clinical Trial of Nepicastat for Post Traumatic Stress Disorder (PTSD) (PHASE2)
- Study of Safety and Potential Efficacy of SYN117 in Cocaine Dependent Volunteers (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SYN117 80 mg CI brief — competitive landscape report
- SYN117 80 mg updates RSS · CI watch RSS
- Biotie Therapies Inc. portfolio CI